275 related articles for article (PubMed ID: 26320862)
21. Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway.
Jakopin Ž
J Med Chem; 2014 Aug; 57(16):6897-918. PubMed ID: 24707857
[TBL] [Abstract][Full Text] [Related]
22. Increased NOD1, but not NOD2, activity in subcutaneous adipose tissue from patients with metabolic syndrome.
Zhou YJ; Liu C; Li CL; Song YL; Tang YS; Zhou H; Li A; Li Y; Weng Y; Zheng FP
Obesity (Silver Spring); 2015 Jul; 23(7):1394-400. PubMed ID: 26052894
[TBL] [Abstract][Full Text] [Related]
23. Role of nucleotide-binding oligomerization domain 1 (NOD1) and its variants in human cytomegalovirus control in vitro and in vivo.
Fan YH; Roy S; Mukhopadhyay R; Kapoor A; Duggal P; Wojcik GL; Pass RF; Arav-Boger R
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7818-E7827. PubMed ID: 27856764
[TBL] [Abstract][Full Text] [Related]
24. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2.
Bertrand MJ; Doiron K; Labbé K; Korneluk RG; Barker PA; Saleh M
Immunity; 2009 Jun; 30(6):789-801. PubMed ID: 19464198
[TBL] [Abstract][Full Text] [Related]
25. Joint NOD2/RIPK2 signaling regulates IL-17 axis and contributes to the development of experimental arthritis.
Vieira SM; Cunha TM; França RF; Pinto LG; Talbot J; Turato WM; Lemos HP; Lima JB; Verri WA; Almeida SC; Ferreira SH; Louzada-Junior P; Zamboni DS; Cunha FQ
J Immunol; 2012 May; 188(10):5116-22. PubMed ID: 22491249
[TBL] [Abstract][Full Text] [Related]
26. RIPK2 inhibitors for disease therapy: Current status and perspectives.
Tian E; Zhou C; Quan S; Su C; Zhang G; Yu Q; Li J; Zhang J
Eur J Med Chem; 2023 Nov; 259():115683. PubMed ID: 37531744
[TBL] [Abstract][Full Text] [Related]
27. Activation of RIPK2-mediated NOD1 signaling promotes proliferation and invasion of ovarian cancer cells via NF-κB pathway.
Zhang W; Wang Y
Histochem Cell Biol; 2022 Feb; 157(2):173-182. PubMed ID: 34825931
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors.
Misehe M; Šála M; Matoušová M; Hercík K; Kocek H; Chalupská D; Chaloupecká E; Hájek M; Boura E; Mertlíková-Kaiserová H; Nencka R
Bioorg Med Chem Lett; 2024 Jan; 97():129567. PubMed ID: 38008339
[TBL] [Abstract][Full Text] [Related]
29. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.
Suebsuwong C; Dai B; Pinkas DM; Duddupudi AL; Li L; Bufton JC; Schlicher L; Gyrd-Hansen M; Hu M; Bullock AN; Degterev A; Cuny GD
Eur J Med Chem; 2020 Aug; 200():112417. PubMed ID: 32505849
[TBL] [Abstract][Full Text] [Related]
30. Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.
Suebsuwong C; Pinkas DM; Ray SS; Bufton JC; Dai B; Bullock AN; Degterev A; Cuny GD
Bioorg Med Chem Lett; 2018 Feb; 28(4):577-583. PubMed ID: 29409752
[TBL] [Abstract][Full Text] [Related]
31. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling.
Damgaard RB; Fiil BK; Speckmann C; Yabal M; zur Stadt U; Bekker-Jensen S; Jost PJ; Ehl S; Mailand N; Gyrd-Hansen M
EMBO Mol Med; 2013 Aug; 5(8):1278-95. PubMed ID: 23818254
[TBL] [Abstract][Full Text] [Related]
32. XIAP controls RIPK2 signaling by preventing its deposition in speck-like structures.
Ellwanger K; Briese S; Arnold C; Kienes I; Heim V; Nachbur U; Kufer TA
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31350258
[TBL] [Abstract][Full Text] [Related]
33. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
Yan Y; Zhou B; Qian C; Vasquez A; Kamra M; Chatterjee A; Lee YJ; Yuan X; Ellis L; Di Vizio D; Posadas EM; Kyprianou N; Knudsen BS; Shah K; Murali R; Gertych A; You S; Freeman MR; Yang W
Nat Commun; 2022 Feb; 13(1):669. PubMed ID: 35115556
[TBL] [Abstract][Full Text] [Related]
34. Synthetic Biology Reveals the Uniqueness of the RIP Kinase Domain.
Chirieleison SM; Kertesy SB; Abbott DW
J Immunol; 2016 May; 196(10):4291-7. PubMed ID: 27045108
[TBL] [Abstract][Full Text] [Related]
35. Regulation of Nod1-mediated signaling pathways.
da Silva Correia J; Miranda Y; Leonard N; Hsu J; Ulevitch RJ
Cell Death Differ; 2007 Apr; 14(4):830-9. PubMed ID: 17186025
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs).
Yuan X; Chen Y; Tang M; Wei Y; Shi M; Yang Y; Zhou Y; Yang T; Liu J; Liu K; Deng D; Zhang C; Chen L
J Med Chem; 2022 Jul; 65(13):9312-9327. PubMed ID: 35709396
[TBL] [Abstract][Full Text] [Related]
37. NOD1 and NOD2 signalling links ER stress with inflammation.
Keestra-Gounder AM; Byndloss MX; Seyffert N; Young BM; Chávez-Arroyo A; Tsai AY; Cevallos SA; Winter MG; Pham OH; Tiffany CR; de Jong MF; Kerrinnes T; Ravindran R; Luciw PA; McSorley SJ; Bäumler AJ; Tsolis RM
Nature; 2016 Apr; 532(7599):394-7. PubMed ID: 27007849
[TBL] [Abstract][Full Text] [Related]
38. Identification of benzofused five-membered sultams, potent dual NOD1/NOD2 antagonists in vitro and in vivo.
Ma Y; Li X; Pei Y; Ye J; Wei X; Yang J; Si G; Tian J; Dong Y; Liu G
Eur J Med Chem; 2020 Oct; 204():112575. PubMed ID: 32731185
[TBL] [Abstract][Full Text] [Related]
39. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
[TBL] [Abstract][Full Text] [Related]
40. Assaying RIPK2 Activation by Complex Formation.
Steinle H; Ellwanger K; Kufer TA
Methods Mol Biol; 2022; 2523():133-150. PubMed ID: 35759195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
